Last reviewed · How we verify
Bortezomib, Dexamethasone, Rituximab
Bortezomib, Dexamethasone, Rituximab is a Proteasome inhibitor Small molecule drug developed by European Myeloma Network B.V.. It is currently in Phase 2 development for Multiple myeloma, Mantle cell lymphoma. Also known as: Velcade, MabThera.
Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells.
Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells. Used for Multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | Bortezomib, Dexamethasone, Rituximab |
|---|---|
| Also known as | Velcade, MabThera |
| Sponsor | European Myeloma Network B.V. |
| Drug class | Proteasome inhibitor |
| Target | 26S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bortezomib specifically targets the 26S proteasome, a complex responsible for degrading ubiquitinated proteins. By inhibiting this complex, bortezomib induces endoplasmic reticulum stress and activates pro-apoptotic pathways, ultimately leading to cancer cell death. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma cells.
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (PHASE4)
- Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients (PHASE2)
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies (EARLY_PHASE1)
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (PHASE3)
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (PHASE2)
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib, Dexamethasone, Rituximab CI brief — competitive landscape report
- Bortezomib, Dexamethasone, Rituximab updates RSS · CI watch RSS
- European Myeloma Network B.V. portfolio CI
Frequently asked questions about Bortezomib, Dexamethasone, Rituximab
What is Bortezomib, Dexamethasone, Rituximab?
How does Bortezomib, Dexamethasone, Rituximab work?
What is Bortezomib, Dexamethasone, Rituximab used for?
Who makes Bortezomib, Dexamethasone, Rituximab?
Is Bortezomib, Dexamethasone, Rituximab also known as anything else?
What drug class is Bortezomib, Dexamethasone, Rituximab in?
What development phase is Bortezomib, Dexamethasone, Rituximab in?
What are the side effects of Bortezomib, Dexamethasone, Rituximab?
What does Bortezomib, Dexamethasone, Rituximab target?
Related
- Drug class: All Proteasome inhibitor drugs
- Target: All drugs targeting 26S proteasome
- Manufacturer: European Myeloma Network B.V. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for Mantle cell lymphoma
- Also known as: Velcade, MabThera
- Compare: Bortezomib, Dexamethasone, Rituximab vs similar drugs
- Pricing: Bortezomib, Dexamethasone, Rituximab cost, discount & access